reference/26480282

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26480282

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study
endingPage	112
issn	1527-3792 0022-5347
issueIdentifier	1
pageRange	106-112
publicationName	The Journal of urology
startingPage	106
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4c4d04ee4d61b0a7c18d50094e1677b4 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_15efc6190f3be0fb3582a4f2b162ac6c http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d62f51386142d8e7576b9b70134d6e59
bibliographicCitation	Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2019 Jan;201(1):106–11. doi: 10.1016/j.juro.2018.07.065. PMID: 30076904.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0cee0b543434fd92f9b950470942b889 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6125867b520bf648ecc21a5d58552201 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b1e6934b3f4bb655cedcab76c9eb44b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8503e1fbf599dd58d01d42e396fa2f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a8fee87dede95cb133b0cb919a0d082 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_187dd1118ff782e01b06002a365a8e2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c51142370fea8ec0dd939da209bcf93 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60970449f1c62beea7b56f7f42339831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5d772ae9ea9562d5be9c70561806384 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f51620f52af69ceab1689e8be39c5457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db6a5215ed97dc1c9a78bd201c91389c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57cb61b5b0f3302cbe34ed05748af8c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76f4b4c1af032775aaa1a1d2542aa2b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb7d57ddbd3fc2a38362d32d1a9227b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3891dbbf9e66e0fcd347302a7aadbe11
date	201901
identifier	https://doi.org/10.1016/j.juro.2018.07.065 https://pubmed.ncbi.nlm.nih.gov/30076904
isPartOf	https://portal.issn.org/resource/ISSN/1527-3792 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5331 https://portal.issn.org/resource/ISSN/0022-5347
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS
discusses	http://id.nlm.nih.gov/mesh/M0026444 http://id.nlm.nih.gov/mesh/M0545267
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D058891Q000627 http://id.nlm.nih.gov/mesh/D011471Q000473 http://id.nlm.nih.gov/mesh/D011159 http://id.nlm.nih.gov/mesh/D011471Q000628
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D017430Q000097 http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D011471Q000401 http://id.nlm.nih.gov/mesh/D011468 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D060787 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D057832 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_831b83078073530f97985cd8e6573484 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Total number of triples: 59.